Free press releases distribution network?

Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New Molecular Assay Provides Healthcare Facilities with a Simple, Efficient Way to Detect Dangerous Superbug - BD MAX™ Cdiff Assay Receives FDA Clearance (NYSE: BDX) - BD.com
New Molecular Assay Provides Healthcare Facilities with a Simple, Efficient Way to Detect Dangerous Superbug

 

PRZOOM - /newswire/ - Baltimore, MD, United States, 2013/04/09 - BD MAX™ Cdiff Assay Receives FDA Clearance (NYSE: BDX) - BD.com. NYSE: BDX

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

BD Diagnostics, a segment of BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it received FDA clearance to market the BD MAX™ Cdiff Assay in the United States. The assay is performed on the fully-automated BD MAX™ System and is designed to rapidly and accurately detect the toxin B gene (tcdB), which has been shown to be essential to cause disease, in patients suspected of Clostridium difficile infection (CDI).

Rapid, accurate identification of patients with CDI enables timely and appropriate therapy and infection control interventions to prevent the spread of this infection in healthcare institutions. Use of molecular testing has been proven to reduce the number of healthcare facility-associated cases of CDI.[i] The assay was CE-marked in March 2012 and has demonstrated excellent performance in Europe.[ii]

“The BD MAX Cdiff assay is a simple, easy-to-use, fully-automated method for detection of these dangerous bacteria,” said Tom Polen, President, BD Diagnostics Diagnostic Systems. “FDA clearance of the BD MAX Cdiff assay gives our customers the ability to balance productivity and cost as they perform laboratory testing for an expanding menu of infectious diseases.”

According to the U.S. Centers for Disease Control and Prevention, CDIs are a growing threat in hospitals, nursing homes and other healthcare settings. Infection rates are at historically high levels, killing 14,000 Americans each year and adding more than $1 billion in excess costs to the healthcare system. The National Action Plan to Prevent Healthcare-Associated Infections is targeting a 30 percent reduction of CDI rates, which may be prevented through a combination of infection control interventions and appropriate use of antibiotics.[iii]

The BD MAX™ Cdiff assay is the third FDA-cleared assay on the BD MAX™ System. Other available assays include BD MAX™ MRSA for the detection of methicillin-resistant Staphylococcus aureus and BD MAX™ GBS for the detection of Group B Streptococcus. Both assays were categorized by FDA as CLIA Moderate Complexity tests. This latest milestone represents further confirmation of BD’s commitment to rapidly expand its menu, offering laboratories a broad range of molecular tests that meet both their current and future clinical needs.

About BD
BD (bd.com) is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

[i]Catanzaro et al., 2012 Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital. AJIC 40:663-666
[ii]Le Guern et al., 2012 Evaluation of a New Molecular Test, the BD Max Cdiff, for Detection of Toxigenic Clostridium difficile in Fecal Samples. J. Clin. Microbiol. 2012, 50:3089-3090
[iii]MMWR. March 9, 2012. Vital Signs: Preventing Clostridium difficile Infections.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Becton, Dickinson and Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Molecular Assay Provides Healthcare Facilities with a Simple, Efficient Way to Detect Dangerous Superbug

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BD |
Contact: Jamie Yacco - BD.com 
201-847-4796 Jamie_Yacco[.]bd.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Becton, Dickinson and Company / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today